<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34742344</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1756-8722</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of hematology &amp; oncology</Title>
          <ISOAbbreviation>J Hematol Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.</ArticleTitle>
        <Pagination>
          <StartPage>186</StartPage>
          <MedlinePgn>186</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">186</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13045-021-01196-x</ELocationID>
        <Abstract>
          <AbstractText>Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. Combining VEGF-signalling inhibitors with PARPi has enhanced clinical benefit in OC. To study drivers of efficacy when combining PARP inhibition and VEGF-signalling, a cohort of patient-derived ovarian cancer xenografts (OC-PDXs), representative of the molecular characteristics and drug sensitivity of patient tumours, were treated with the PARPi olaparib and the VEGFR inhibitor cediranib at clinically relevant doses. The combination showed broad anti-tumour activity, reducing growth of all OC-PDXs, regardless of the homologous recombination repair (HRR) mutational status, with greater additive combination benefit in tumours poorly sensitive to platinum and olaparib. In orthotopic models, the combined treatment reduced tumour dissemination in the peritoneal cavity and prolonged survival. Enhanced combination benefit was independent of tumour cell expression of receptor tyrosine kinases targeted by cediranib, and not associated with change in expression of genes associated with DNA repair machinery. However, the combination of cediranib with olaparib was effective in reducing tumour vasculature in all the OC-PDXs. Collectively our data suggest that olaparib and cediranib act through complementary mechanisms affecting tumour cells and tumour microenvironment, respectively. This detailed analysis of the combined effect of VEGF-signalling and PARP inhibitors in OC-PDXs suggest that despite broad activity, there is no dominant common mechanistic inter-dependency driving therapeutic benefit.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Bizzaro</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fuso Nerini</LastName>
            <ForeName>Ilaria</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taylor</LastName>
            <ForeName>Molly A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Early Oncology, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anastasia</LastName>
            <ForeName>Alessia</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Russo</LastName>
            <ForeName>Massimo</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Damia</LastName>
            <ForeName>Giovanna</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guffanti</LastName>
            <ForeName>Federica</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guana</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ostano</LastName>
            <ForeName>Paola</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Minoli</LastName>
            <ForeName>Lucia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Veterinary Medicine, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hattersley</LastName>
            <ForeName>Maureen M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Early Oncology, AstraZeneca, Boston, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arnold</LastName>
            <ForeName>Stephanie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Early Oncology, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramos-Montoya</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Early Oncology, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Williamson</LastName>
            <ForeName>Stuart C</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Early Oncology, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galbiati</LastName>
            <ForeName>Alessandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Early Oncology, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Urosevic</LastName>
            <ForeName>Jelena</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Early Oncology, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leo</LastName>
            <ForeName>Elisabetta</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Early Oncology, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cavallaro</LastName>
            <ForeName>Ugo</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Gynecological Oncology Research, Istituto Europeo di Oncologia IRCCS, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghilardi</LastName>
            <ForeName>Carmen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Barry</LastName>
            <ForeName>Simon T</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Early Oncology, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Bani</LastName>
            <ForeName>Maria Rosa</ForeName>
            <Initials>MR</Initials>
            <Identifier Source="ORCID">0000-0001-8178-1432</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy. mariarosa.bani@marionegri.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Giavazzi</LastName>
            <ForeName>Raffaella</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Hematol Oncol</MedlineTA>
        <NlmUniqueID>101468937</NlmUniqueID>
        <ISSNLinking>1756-8722</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010793">Phthalazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000067856">Poly(ADP-ribose) Polymerase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NQU9IPY4K9</RegistryNumber>
          <NameOfSubstance UI="C500926">cediranib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WOH1JD9AR8</RegistryNumber>
          <NameOfSubstance UI="C531550">olaparib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019398" MajorTopicYN="N">Genes, BRCA1</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024522" MajorTopicYN="N">Genes, BRCA2</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010793" MajorTopicYN="N">Phthalazines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067856" MajorTopicYN="N">Poly(ADP-ribose) Polymerase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">BRCA</Keyword>
        <Keyword MajorTopicYN="Y">Cediranib</Keyword>
        <Keyword MajorTopicYN="Y">Olaparib</Keyword>
        <Keyword MajorTopicYN="Y">Ovarian cancer</Keyword>
        <Keyword MajorTopicYN="Y">PARP inhibitor</Keyword>
        <Keyword MajorTopicYN="Y">Patient-derived xenograft</Keyword>
        <Keyword MajorTopicYN="Y">VEGF pathway inhibitor</Keyword>
      </KeywordList>
      <CoiStatement>MAT, MMH, SA, AR, SCW, AG, JU, EL, STB are AstraZeneca employees and shareholders. All other authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>20</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34742344</ArticleId>
        <ArticleId IdType="pmc">PMC8572452</ArticleId>
        <ArticleId IdType="doi">10.1186/s13045-021-01196-x</ArticleId>
        <ArticleId IdType="pii">10.1186/s13045-021-01196-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, et al.  The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020 doi: 10.1016/j.annonc.2020.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.annonc.2020.06.004</ArticleId>
            <ArticleId IdType="pubmed">32569725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al.  Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–2428. doi: 10.1056/NEJMoa1911361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1911361</ArticleId>
            <ArticleId IdType="pubmed">31851799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee SN, Lord CJ. First-line PARP inhibition in ovarian cancer—standard of care for all? Nat Rev Clin Oncol. 2020;17:136–137. doi: 10.1038/s41571-020-0335-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-020-0335-9</ArticleId>
            <ArticleId IdType="pubmed">32051558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, et al.  FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncologist. 2021;26:e164–e172. doi: 10.1002/onco.13551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/onco.13551</ArticleId>
            <ArticleId IdType="pmc">PMC7794199</ArticleId>
            <ArticleId IdType="pubmed">33017510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389–4400. doi: 10.1158/0008-5472.CAN-04-4409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-4409</ArticleId>
            <ArticleId IdType="pubmed">15899831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JF, Barry WT, Birrer M, Lee J-M, Buckanovich RJ, Fleming GF, et al.  Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019;30:551–557. doi: 10.1093/annonc/mdz018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz018</ArticleId>
            <ArticleId IdType="pmc">PMC6503628</ArticleId>
            <ArticleId IdType="pubmed">30753272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, et al.  Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 2014;74:6980–6990. doi: 10.1158/0008-5472.CAN-14-0274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-0274</ArticleId>
            <ArticleId IdType="pubmed">25304260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Huniti N, Petersson K, Tang W, Masson E, Li J. Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer. Br J Clin Pharmacol. 2018;84:726–737. doi: 10.1111/bcp.13495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.13495</ArticleId>
            <ArticleId IdType="pmc">PMC5867133</ArticleId>
            <ArticleId IdType="pubmed">29274100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R, et al.  Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol. 2014;184:1050–1061. doi: 10.1016/j.ajpath.2013.12.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2013.12.030</ArticleId>
            <ArticleId IdType="pubmed">24508126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivy SP, Liu JF, Lee J-M, Matulonis UA, Kohn EC. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs. 2016;25:597–611. doi: 10.1517/13543784.2016.1156857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.2016.1156857</ArticleId>
            <ArticleId IdType="pubmed">26899229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, et al.  Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med. 2019 doi: 10.1126/scitranslmed.aav4508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aav4508</ArticleId>
            <ArticleId IdType="pmc">PMC6626544</ArticleId>
            <ArticleId IdType="pubmed">31092693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Al-Huniti N, Henningsson A, Tang W, Masson E. Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer. Br J Clin Pharmacol. 2017;83:1723–1733. doi: 10.1111/bcp.13266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.13266</ArticleId>
            <ArticleId IdType="pmc">PMC5510068</ArticleId>
            <ArticleId IdType="pubmed">28213941</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
